Dernières nouvelles pour Merus (NASDAQ:MRUS) Stock

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV

Wells Fargo analyst Eva Fortea Verdejo maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight and lowers the price target from $91 to $89.

News

Price Target

Analyst Ratings

MRUS

Wells Fargo Maintains Overweight on Merus, Lowers Price Target to $89

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 137.29 percent decrease over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $26.49 million which beat the analyst consensus estimate of $7.82 million by 238.85 percent. This is a 235.76 percent increase over sales of $7.89 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Merus Q1 EPS $(1.40) Misses $(1.10) Estimate, Sales $26.49M Beat $7.82M Estimate

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation &nbsp;
- Conference call on&nbsp;Thursday, May 22&nbsp;at&nbsp;5:30 p.m. ET&nbsp;to discuss full ASCO&#xAE;&nbsp;data set
UTRECHT, The Netherlands&nbsp;and&nbsp;CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=yI2ecVsdRdXGdF2kI9WTwgqSchuYceNZul-sZuLiDMAEyEDBbIn5uDoCY8xIDJxN6qJWid8zPIakPcw51WnyrA==">Merus</a> N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE;&nbsp;and ADClonics&#xAE;), today announced the acceptance of an abstract for presentation at the 2025&nbsp;American Society of Clinical Oncology&#xAE;&nbsp;(ASCO&#xAE;) Annual Meeting, being held in&nbsp;Chicago, Illinois&nbsp;on&nbsp;May 30- June 3, 2025.
An updated analysis of the interim clinical data from the phase 2 trial of petosemtamab with pembrolizumab as 1L treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) will be presented in a poster at 2025 ASCO&#xAE;. The presentation will include data on the entire 45 patient dataset and follows the early clinical efficacy and encouraging safety data previously presented at 2024 ASCO&#xAE;.

Merus Says Petosemtamab In Combination With Pembrolizumab In 1L PD-L1+ R/M HNSCC Interim Clinical Data Selected For Poster Presentation At 2025 ASCO Annual Meeting

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $83 price target.

Reiteration

Needham Reiterates Buy on Merus, Maintains $83 Price Target

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $109 price target.

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $73 to $70.

B of A Securities Maintains Buy on Merus, Lowers Price Target to $70

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

HC Wainwright & Co. Reiterates Buy on Merus, Maintains $85 Price Target

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $85 to $83.

Needham Maintains Buy on Merus, Lowers Price Target to $83

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(3.35) per share which beat the analyst consensus estimate of $(3.80) by 11.84 percent. The company reported quarterly sales of $36.133 which missed the analyst consensus estimate of $38.544 million by 100.00 percent.

Merus FY 2024 GAAP EPS $(3.35) Beats $(3.80) Estimate, Sales $36.133 Miss $38.544M Estimate

Shares of Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) are trading higher Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to <a href="https://www.benzinga.com/25/01/42961654/whats-going-on-with-merus-stock-monday">petosemtamab in combination with pembrolizumab.</a>
What To Know: The designation applies to the first-line treatment of adult patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma (r/m HNSCC) with a combined positive score of at least 1.
This marks the second BTD for petosemtamab, following an earlier designation for patients with r/m HNSCC whose disease had progressed after treatment with platinum-based chemotherapy and an anti-PD-1 antibody. The new designation is based on updated data from an ongoing phase 1/2 clinical trial, which initially showed a 67% response rate among 24 evaluable patients.
Breakthrough Therapy designation is intended to expedite the development and review of drugs that show substantial improvement over existing treatments for serious conditions. This status will allow Merus to work closely with the FDA, accelerating regulatory discussions and potentially leading to a faster approval process. 
MRUS Price Action: Merus shares were up 5.40% at $42.37 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021825&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-1024x527.png" alt="" class="wp-image-787550" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-768x395.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/02/43761300/intel-could-be-split-in-two-as-broadcom-and-tsmc-explore-deals-trump-white-house-resists-foreign-ownership-report">Intel Could Be Split In Two As Broadcom And TSMC Explore Deals, Trump White House Resists Foreign Ownership: Report</a></li>
</ul>
Image via Shutterstock.

Movers

Merus Shares Are Up Today: What's Going On?

WIIM

Merus shares are trading higher after the company announced the FDA granted breakthrough therapy designation for Petosemtamab plus Pembrolizumab in PD-L1.

Biotech

General

FDA Grants Breakthrough Therapy Designation For Merus's Petosemtamab Plus Pembrolizumab In PD-L1 Positive Head And Neck Cancer

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Ben Kallo initiated coverage on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with an Outperform rating and announced a price target of $448. GE Vernova shares closed at $369.65 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Joseph Catanzaro initiated coverage on Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with an Overweight rating and announced a price target of $84. Merus shares closed at $40.26 on Wednesday. <a href="https://www.benzinga.com/quote/MRUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst George Farmer initiated coverage on Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Sector Outperform rating and announced a price target of $102. Viking Therapeutics shares closed at $29.32 on Wednesday. <a href="https://www.benzinga.com/quote/VKTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Randy Binner initiated coverage on Sunrise Realty Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) with a Buy rating and announced a price target of $15. Sunrise Realty Trust shares closed at $11.47 on Wednesday. <a href="https://www.benzinga.com/quote/SUNS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith initiated coverage on Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Hold rating and announced a price target of C$67. <a href="https://www.benzinga.com/quote/FTS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1006" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118.png" alt="" class="wp-image-780880" style="width:412px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118.png 1006w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118-768x386.png 768w" sizes="(max-width: 1006px) 100vw, 1006px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

SUNS

TSX:FTS

VKTX

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Piper Sandler analyst Joseph Catanzaro initiates coverage on Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight rating and announces Price Target of $84.

Piper Sandler Initiates Coverage On Merus with Overweight Rating, Announces Price Target of $84

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) from Buy to Buy.

Guggenheim Reiterates Buy on Merusto Buy

"This manuscript provides comprehensive data on the safety and efficacy of Bizengri and demonstrates the meaningful results observed in the eNRGy trial," said&nbsp;Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "We continue to make significant progress across our clinical pipeline of important and new cancer therapeutic candidates, all from our own Biclonics&nbsp;antibody technologies."

Merus Says New England Journal Of Medicine Published Results Of Registrational Phase 2 eNRGy Trial For Bizengri

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>). Here&#8217;s <a href="https://www.benzinga.com//node/42936564">what you need to know.</a>
What To Know: Biohaven and Merus will to co-develop three antibody-based therapies, utilizing Merus&#8217; Biclonics platform alongside its own technologies. The collaboration includes two existing Merus programs and one in early research. 
Under the agreement, Merus will receive an upfront payment and a licensing fee once the first antibody drug conjugate (ADC) candidate is selected. In addition, Merus will cover the costs of preclinical antibody development, while Biohaven will manage the preclinical ADC development expenses. 
If any therapies progress to commercialization, the companies plan to share development costs jointly.
&#8220;We believe this collaboration with Merus will accelerate our ability to create highly differentiated multispecific ADCs, leveraging Biohaven&#8217;s innovative conjugation and payload technologies to deliver optimized ADCs with the potential to significantly benefit patients across various cancer types through an enhanced efficacy and safety profile,&#8221; added Brian Lestini, President, Oncology of Biohaven.
Related Link: <a href="https://www.benzinga.com/general/travel/25/01/42958773/united-airlines-earnings-preview-could-airline-impress-investors-after-deltas-strong-guidance">United Airlines Earnings Preview: Could Airline Impress Investors After Delta&#8217;s Strong Guidance?</a>
MRUS Price Action: Merus stock closed 7.75% lower on Monday at $40.45, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Photo: Shutterstock

BHVN

What's Going On With Merus Stock Monday?

Merus shares are trading lower. The company announced a  research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.

Comments

Merus

Actualités

Dernières nouvelles pour Merus (NASDAQ:MRUS) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL